Loading
Almost every drug trial for gallbladder cancer also enrols bile duct cancers, so the evidence comes from mixed groups in which gallbladder cancer is usually a fifth to a half of patients. This entry lists the trials open to people with gallbladder cancer and what each reported for the gallbladder subgroup.
Gallbladder cancer is rarely trialled on its own. In the landmark trials it was one stratum among three: 25 percent of TOPAZ-1 patients had gallbladder cancer (FDA label), KEYNOTE-966 stratified randomisation by site of origin including gallbladder, ABC-06 enrolled gallbladder and ampullary cancer alongside cholangiocarcinoma, SWOG S1815 had 16 percent gallbladder cancer and BILCAP required muscle-invasive gallbladder cancer for entry. HER2 trials are the exception where gallbladder cancer dominates: 53 percent of HERIZON-BTC-01 patients had gallbladder cancer. Subgroup results are sparse and exploratory: in S1815 the triplet improved progression-free but not overall survival more in gallbladder cancer than in cholangiocarcinoma (interaction p 0.01 and 0.28), and in TreeTopp varlitinib gave a non-significant progression-free survival signal in gallbladder cancer (2.9 versus 1.6 months, hazard ratio 0.55, confidence interval crossing 1). Gallbladder-only randomised trials exist mainly in India (POLCAGB, RUGB, NEOGB) and the United States (OPT-IN) and address surgery, radiotherapy and neoadjuvant timing rather than new drugs. The trials linked here are every interventional phase 2 or 3 study on ClinicalTrials.gov or ISRCTN that was open or active in September 2026 and names gallbladder cancer in its conditions or eligibility, with UK sites quoted where the registry lists them.
Shares KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma, PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment, The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma, A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT).
Shares Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors, KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma, PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment, The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma.
Shares Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer, CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors, Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma, A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs.
Shares Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma, A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs, Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer, Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers.
Shares PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment, Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers, Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels, A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors..
Shares ABC-12, Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo), DEBATE, NIFE (AIO-YMO HEP-0315).
Shares Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma, A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs, Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer, A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC).
Shares Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer, Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC), A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement, ABC-12.